Introduction
Leishmaniasis is a parasitic disease which is caused by intracellular protozoans of genus Leishmania. These protozoans are transmitted through bite of infected female phlebotomine sandflies. There are three main types of leishmaniasis: (a) cutaneous leishmaniasis, (b) mucocutaneous leishmaniasis, (c) visceral leishmaniasis (kala azar). Cutaneous leishmaniasis is a localized reaction ( skin ulcers, scars) which is caused by Leishmania tropica and Leishmania aethiopica. It is most commonly found in Brazil, Iran, Syria. Mucocutaneous leishmaniasis (espundia or uta) starts with bite of sandflies and go into mucous membrane through [1] . Leishmania cells have two morphological form: promastigote (with flagella) in the insect host and amastigote form (without flagella) in vertebrate host [2] . Leishmania parasites invade and multiply within host macrophages and decrease cell mediated immune response. They neutralize complement component and prevent the release of macrophage superoxide and nitric oxide and suppress the induction of CD4 and T lymphocytes [3] . It is characterized by fever, hepatosplenomegaly, pancytopenia, loss of appetite, and anaemia. On the basis of symptoms, physical examinations are performed. Enlarged spleen (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) cm) below costal margin and haemoglobin concentration (5) (6) (7) (8) (9) g/dL), white blood cell count (2 000-4 000/mm 3 ), platelet count (100 000-200 000/mm
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3 ) are typical in visceral leishmaniasis.
Amphotericin B is a systemic antifungal agent, also used for treatment of visceral leishmaniasis in India. Due to resistance to antimonials, it is used as alternative drug. But it is highly toxic [4] . Fifteen infusions of 1 mg/kg of amphotericin B are given on alternate days (total dose 15 mg/kg) for treatment of visceral leishmaniasis. After several months or years of initial treatment of visceral leishmaniasis, a cutanious complication i.e. post kala azar dermal leishmaniasis may occur [5] . Both visceral leishmaniasis and tuberculosis are increasing in eastern region of country. Although their etiology and transmission mechanism are different, they share several features. Tuberculosis is immunosuppressive condition that causes progression of latent leishmaniasis to clinical leishmaniasis, and visceral leishmaniasis can produce latent tuberculosis. Treatment of leishmaniasis depends on development of effective immune response which activates macrophages to produce nitric oxide for killing intracellular amastigotes.
Case report
A 48 years old male was admitted to Rajendra Memorial Research Institute of Medical Sciences in Bihar, India on 1st April, 2013 with fever associated with rigor, abdominal pain, weakness, headache, loss of appetite, yellowish discoloration of urine and sclerosis at lower back. He had 20 years back history of pulmonary tuberculosis. On physical examination, patient was conscious, oriented, pulse (84 beats/min), blood pressure (120/80 mmHg) and pallor (+). There was vesicular breath sound from chest and heart sound (s1s2) was audible. His liver and spleen were palpable and enlarged (2 cm There was cyst seen in right kidney. Due to this, his renal function was deranging gradually. Cytological reports and sputum smear were positive for pulmonary tuberculosis in the patient. Antitubercular therapy was started. AKT-FD (four drug regimen: isoniazid 100 mg, rifampicin 150 mg, pyrazinamide 500 mg, ethambutol 267 mg) was prescribed three tablet once in an empty stomach in morning. B-long (pyridoxine sustained release 100 mg) was also prescribed alongwith antitubercular drugs.
Discussion
K ala azar is a vectorborne parasitic disease. Approximately 500 000 cases of visceral leishmaniasis worldwide affect rural population of India, Nepal, Bangladesh, and Sudan. Paromomycin is an aminoglycoside antibiotic given intramuscularly for treatment of kala azar at a dose of 12, 20 mg/kg for 21 d. Sodium stibogluconate is a pentavalent antimonial compound used for treatment of visceral leishmaniasis, but is no longer useful in Bihar because of resistance [6] . Amphotericin B is polyene antibiotic used for treatment of kala-azar, but it causes electrolyte imbalance. Amphotericin B induced hypokalemia is dose-dependent. During amphotericin B therapy, there is defect in distal tubule H + K + ATPase which increases K + elimination results in hypokalemia [7] . A total of 5% dextrose is also infused with amphotericin B to reduce hypokalemia.
Co-infections of tuberculosis and parasitic diseases are increasing public health problem in developing countries. Infection with parasitic diseases alters protective immune response to BCG vaccine against tuberculosis [8] .
Although their etiology and transmission mechanism are different, they share several features. Tuberculosis is immunosuppressive condition that is caused by mycobacterium tuberculosis. Directly observed treatment short course therapy is provided by government free of cost for TB [9] . Annual risk of tuberculosis is estimated at 1.8% which gives incident rates of TB smear positive cases of 90/100 000 person-year, in which Sudan is highly prevelant for TB.
Patient was treated with 15 infusions of amphotericin B (inj. fungizone 11.6 mL) alongwith 5% dextrose every alternate day. After 6th dose, his serum creatinine was increased above normal, so fungizone was withheld. Rest of doses were continued when serum creatinine reached to normal range. He had 20 years past history of pulmonary tuberculosis. On physical examination, there was vesicular breath sound of chest. He felt difficulty in breathing, so his chest X-ray was done. There was increased bronchovascular marking encysted pleural effusion in lower side of right lung. Fine needle aspiration cytology showed abnormalities in pleural fluid. Pleural fluid was straw in color, hazy in appearance, presence of fibrin coagulum. Cell [10] . Alongwith this combination, pyridoxine 100 mg/d is given to reduce isoniazid toxicity.
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Comments

Background
It is a case report of 48 years old male with complaints of fever with rigor, abdominal pain, weakness, loss of appetite, yellowish discoloration of urine and sclerosis at lower back. His treatment was initiated. X-ray, ultrasonography guided fine needle aspiration cytology and cytological reports confirmed the co-infection of pulmonary tuberculosis and visceral leishmaniasis in the patient.
Research frontiers
Physical examinations of the patient were done. The felt difficulty in breathing, so his chest X-ray was done. There was increased bronchovascular marking encysted pleural effusion in lower side of right lung. Fine 
Innovations & breakthroughs
The current article highlighted the increasing rate of co-infection of visceral leishmaniasis and pulmonary tuberculosis particularly in rural India. The article also suggests the treatment strategies.
Applications
V isceral leishmaniasis is a chronic infection that results into immunological dysfunction which predisposes to pulmonary infections. Tuberculosis is an immunosuppressive condition that progresses latent leishmaniasis and results in clinical leishmaniasis and visceral leishmaniasis can reactivate latent tuberculosis. Monitoring of the patient is necessary and proper treatment strategies are also required.
Peer review
This is a good endeavor by the authors who have undertaken the case study of a person with visceral leishmaniasis and latent tuberculosis. They concluded that co-infection of visceral leishmaniasis and pulmonary tuberculosis is a real threat in developing countries. These types of co-infection inhibit host's immune system. There is a need of cost effective diagnostic and therapeutic facilities for these co-infections.
